All In Biotech

Drug Trial Radar · NCT00147719

WelChol® With Metformin in Treating Patients With Type 2 Diabetes

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of WelChol® in Type 2 Diabetics With Inadequate Glycemic Control on Metformin Monotherapy or Metformin Therapy in Combination With Other Oral Anti-Diabetic Agents

Last checked: Nov 19, 2026Latest source record: Jan 18, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

300

Actual

Start

Jun 2004

Primary completion

Jul 2006

Study completion Jul 2006

Sponsor

Lead sponsor
Daiichi SankyoDaiichi Sankyo (DSNKY)
Sponsor type
Industry
First posted
Sep 7, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to see how safe and effective and tolerable the use of colesevelam hydrochloride is for type 2 diabetes when added to metformin alone or in combination with other anti-diabetic drugs.

Conditions

  • Type 2 Diabetes

Interventions

  • Colesevelam hydrochlorideDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To assess the additional lowering of HbA1C achieved by addition of colesevelam hydrochloride to current antidiabetic therapy

Locations

48 sites in 3 countries. Site status is shown where the registry gives one.

  • CRO

    Jonesboro, Arkansas

  • Site not named

    Beverly Hills, California

  • Site not named

    Carmichael, California

  • Site not named

    Fresno, California

  • Site not named

    Irvine, California

  • Site not named

    La Jolla, California

  • Site not named

    Los Gatos, California

  • Site not named

    San Diego, California

  • Site not named

    Spring Valley, California

  • Site not named

    West Hills, California

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Coco Beach, Florida

  • Site not named

    Largo, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Pembroke Pines, Florida

  • Site not named

    West Palm Beach, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Evansville, Indiana

  • Site not named

    Louisville, Kentucky

  • Site not named

    Detroit, Michigan

  • Site not named

    Troy, Michigan

  • Site not named

    Edina, Minnesota

  • Site not named

    Chesterfield, Missouri

  • Site not named

    Bozeman, Montana

  • Site not named

    Butte, Montana

  • Site not named

    Las Vegas, Nevada

  • Site not named

    Rochester, New York

  • Site not named

    Charlotte, North Carolina

  • Site not named

    Winston-Salem, North Carolina

  • Site not named

    Cincinnati, Ohio

  • Site not named

    Cleveland, Ohio

  • Site not named

    Lyndhurst, Ohio

  • Site not named

    Marion, Ohio

  • Site not named

    Oklahoma City, Oklahoma

  • Site not named

    Tulsa, Oklahoma

  • Site not named

    Portland, Oregon

  • Site not named

    Beaver, Pennsylvania

  • Site not named

    Charleston, South Carolina

  • Site not named

    Columbia, South Carolina

  • Site not named

    Morristown, Tennessee

Showing 40 of 48 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.